Ipsen Pledges Ambitious Action on Climate Change
27 Oktober 2021 - 7:00AM
Business Wire
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today has pledged to play its
part in securing global net-zero emissions, ahead of the COP26
conference in Glasgow, UK, next month. Ipsen is proud to have
joined the Business Ambition for 1.5°C1 campaign and is committed
to science-based greenhouse-gas (GHG) emissions reductions,
including:
- Halving the absolute GHG emissions of Ipsen’s facilities and
fleet (Scope 12 & Scope 23) by 20304
- Working with up and downstream value-chain partners to deliver
science-based Scope 35 emissions reductions by 2030
Ipsen has already started to accelerate action on climate
change. Over 85% of Ipsen’s global electricity use is already from
renewable sources. Ipsen is also making its facilities more
efficient, investing in innovative heat-recovery technology and
transforming its fleet energy mix.
As a transition step on its pathway to net zero, Ipsen is also
committing to climate-compensation measures from 2030 for the
emissions not yet removed from its value chain. Even though such
offset will never be a substitute for science-based emissions
reductions, they still have an important role in preserving or
enhancing existing carbon stocks and thus limit the worst impacts
of climate change.
Given the scale of the climate challenge, Ipsen believes
everyone has a role to play. Together with the Company’s
value-chain partners and peers within the Business Ambition for
1.5°C campaign, Ipsen can achieve the positive change needed for
future generations.
David Loew, Chief Executive Officer, commented:
“One of the responsibilities to which I feel most deeply
connected is the need to ensure that environmental sustainability,
particularly minimizing our impact on climate, remains a core part
of our approach. We have all seen the devastating impact of climate
change. There is no doubt in my mind that this is one of the
defining challenges of our time. The actions taken today will
determine the impact felt by future generations. This is why our
environmental approach is fully integrated into our strategy:
Focus. Together. For patients & society”.
1 Business Ambition for 1.5°C is a global coalition of United
Nations agencies, business and industry leaders, pushing climate
ambition beyond the minimum to a global net-zero target, in line
with a 1.5°C future. 2 GHG emissions are categorized into three
groups or 'Scopes' by the most widely-used international accounting
tool, the GHG Protocol. Scope 1 emissions are the GHG emissions
from direct operations including facility heat sources, refrigerant
gasses and fleet. 3 Scope 2 emissions are the GHG emissions from
purchased electricity. 4 Targets listed are compared to the 2019
base-year performance. 5 Scope 3 emissions are indirect GHG
emissions from upstream and downstream value-chain sources. The
description and boundaries of Ipsen’s Scope 3 categories are
published annually in the Company’s Universal Registration
Document; visit ipsen.com.
Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused
on transformative medicines in Oncology, Rare Disease and
Neuroscience; it also has a well-established Consumer Healthcare
business. With total sales of over €2.5bn in FY 2020, Ipsen sells
more than 20 medicines in over 115 countries, with a direct
commercial presence in more than 30 countries. The Company’s
research and development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has
around 5,700 colleagues worldwide and is listed in Paris (Euronext:
IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
Forward-looking statements
The forward-looking statements, objectives and targets contained
herein are based on Ipsen’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events
to differ materially from those anticipated herein. All of the
above risks could affect Ipsen’s future ability to achieve its
financial targets, which were set assuming reasonable macroeconomic
conditions based on the information available today. Use of the
words ‘believes’, ‘anticipates’ and ‘expects’ and similar
expressions are intended to identify forward-looking statements,
including Ipsen’s expectations regarding future events, including
regulatory filings and determinations. Moreover, the targets
described in this document were prepared without taking into
account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives
are based on data and assumptions regarded as reasonable by Ipsen.
These targets depend on conditions or facts likely to happen in the
future, and not exclusively on historical data. Actual results may
depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up
never being launched on the market or reaching its commercial
targets, notably for regulatory or competition reasons. Ipsen must
face or might face competition from generic products that might
translate into a loss of market share. Furthermore, the Research
and Development process involves several stages each of which
involves the substantial risk that Ipsen may fail to achieve its
objectives and be forced to abandon its efforts with regards to a
product in which it has invested significant sums. Therefore, Ipsen
cannot be certain that favorable results obtained during
preclinical trials will be confirmed subsequently during clinical
trials, or that the results of clinical trials will be sufficient
to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic
factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and
health care legislation; global trends toward health care cost
containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Ipsen's
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of Ipsen’s patents and other protections for
innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions. Ipsen also depends on
third parties to develop and market some of its products which
could potentially generate substantial royalties; these partners
could behave in such ways which could cause damage to Ipsen’s
activities and financial results. Ipsen cannot be certain that its
partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of
Ipsen’s partners could generate lower revenues than expected. Such
situations could have a negative impact on Ipsen’s business,
financial position or performance. Ipsen expressly disclaims any
obligation or undertaking to update or revise any forward-looking
statements, targets or estimates contained in this press release to
reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so
required by applicable law. Ipsen’s business is subject to the risk
factors outlined in its registration documents filed with the
French Autorité des Marchés Financiers. The risks and uncertainties
set out are not exhaustive and the reader is advised to refer to
Ipsen’s 2020 Universal Registration Document, available on
ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211026006178/en/
Investors Craig Marks
Vice President, Investor Relations +44 7584 349 193
Adrien Dupin de Saint-Cyr Investor Relations Manager +33
6 64 26 17 49
Media Gwenan White
Executive Vice President, Communications and External Affairs +44
7876 391 429
Fanny Allaire Global Communications Director + 33 6 08 91
92 55
Ipsen (EU:IPN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ipsen (EU:IPN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024